Expanded coverage allowed companies looking "beyond antibodies" more in-depth presentations on the entire spectrum of topics related to improving the efficiency of developing and producing next generation and novel molecules. Presenters focused on the implementation of disruptive technologies and innovative solutions to improve speed and decrease cost of development. Case studies highlighted recent successes that companies have achieved to overcome the scientific and technical challenges related to the development, scale up and characterization of novel molecules.
2012 Sessions Included:
- Scale Up and Transfer of Complex Biologics - Successful Approaches and Alternatives
- Advances in Half-Life Extension
- Novel Approaches and Technologies to Overcome the Challenges of Downstream Processing
- Development and Production of Drug Conjugates
- Analytical Approaches to Developing Novel and Enhanced Molecules
- Disruptive Technologies Causing Paradigm Shifts in Upstream and Downstream Processing
- Featured Presentations: From Development to Manufacturing of Biobetters, Biosimilars and Novel Biologics
- New Approaches & Strategies for Characterization and Comparability
- Development and Production of Next Generation and Novel Molecules